Q2 2025 EPS Estimates for Hologic, Inc. Increased by Zacks Research (NASDAQ:HOLX)

Hologic, Inc. (NASDAQ:HOLX) – Stock analysts at Zacks Research boosted their Q2 2025 earnings per share estimates for Hologic in a research report issued to clients and investors on Wednesday, April 10th. Zacks Research analyst R. Anand now anticipates that the medical equipment provider will earn $1.11 per share for the quarter, up from their previous estimate of $1.10. The consensus estimate for Hologic’s current full-year earnings is $4.02 per share. Zacks Research also issued estimates for Hologic’s FY2025 earnings at $4.28 EPS.

A number of other research analysts have also recently commented on HOLX. Evercore ISI upped their price target on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and raised their price target for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. William Blair restated an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. Raymond James lifted their price objective on Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Finally, UBS Group lifted their price objective on Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. Six analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Hologic currently has an average rating of “Hold” and a consensus price target of $87.00.

Hologic Stock Down 3.1 %

Shares of NASDAQ:HOLX opened at $75.11 on Monday. Hologic has a 1 year low of $64.02 and a 1 year high of $87.88. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. The business has a fifty day moving average price of $75.66 and a two-hundred day moving average price of $72.46. The company has a market capitalization of $17.63 billion, a PE ratio of 35.60, a price-to-earnings-growth ratio of 2.62 and a beta of 1.00.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The business’s revenue for the quarter was down 5.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.07 EPS.

Insider Buying and Selling at Hologic

In other news, CFO Karleen Marie Oberton sold 14,940 shares of the business’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the transaction, the chief financial officer now owns 103,916 shares in the company, valued at $7,793,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Karleen Marie Oberton sold 14,940 shares of the business’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the transaction, the chief financial officer now owns 103,916 shares in the company, valued at $7,793,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the transaction, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,846 shares of company stock worth $2,473,443. 1.75% of the stock is owned by insiders.

Institutional Investors Weigh In On Hologic

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of Hologic by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 27,882,301 shares of the medical equipment provider’s stock valued at $2,141,919,000 after acquiring an additional 381,608 shares during the period. BlackRock Inc. boosted its position in shares of Hologic by 1.2% in the first quarter. BlackRock Inc. now owns 23,762,174 shares of the medical equipment provider’s stock worth $1,917,607,000 after purchasing an additional 282,787 shares during the period. State Street Corp increased its stake in shares of Hologic by 0.8% in the first quarter. State Street Corp now owns 11,426,634 shares of the medical equipment provider’s stock worth $877,794,000 after purchasing an additional 94,561 shares in the last quarter. Macquarie Group Ltd. raised its position in shares of Hologic by 227.2% during the 2nd quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock valued at $435,485,000 after purchasing an additional 4,363,687 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in shares of Hologic by 4.5% during the 4th quarter. Victory Capital Management Inc. now owns 5,055,048 shares of the medical equipment provider’s stock valued at $361,183,000 after buying an additional 216,958 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.